Farms.com Home   News

Feds order avian influenza vaccine to protect individuals most at risk

The Public Health Agency of Canada (PHAC) is taking proactive measures to protect the health of Canadian citizens by securing a supply of a human vaccine against avian influenza.

While the current risk to the public remains low, individuals with higher-level exposure to infected animals are at increased risk.

Canada reported its first domestically acquired human case of avian influenza A (H5N1) on Nov. 9, 2024. To date, there has been no evidence of sustained person-to-person spread of the virus in any of the cases identified globally. However, avian influenza has the potential to cause serious illness in people.

PHAC will provide vaccines to provinces and territories based on a risk-based approach, with 60 per cent of available doses going to provinces and territories and 40 per cent kept in a federal stockpile for national preparedness.

Chief Public Health Officer Dr. Theresa Tam said provinces and territories will make decisions on the potential use and administration of their respective vaccination programs in the context of local risk conditions.

“By making human vaccines against avian influenza available for potential use in individuals at increased risk of exposure to avian influenza as part of our readiness, we are enhancing our capacity to protect people in Canada and respond rapidly to emerging public health challenges,” Tam said.

Canada’s National Advisory Committee on Immunization (NACI) has also released preliminary guidance on the use of human vaccines against avian influenza in a non-pandemic context.

Click here to see more...

Trending Video

Leman Swine Conference: Vaccination strategies to reduce PRRS virus recombination

Video: Leman Swine Conference: Vaccination strategies to reduce PRRS virus recombination

Dr. Jay Calvert, Research Director with Zoetis, recently spoke to The Pig Site’s Sarah Mikesell at the 2023 Leman Swine Conference in St. Paul, Minnesota, USA, about his conference presentation on porcine reproductive and respiratory syndrome (PRRS) virus recombination.

“The number one problem in PRRS these days from a vaccine point of view is the emergence of new strains of PRRS. Since the beginning, we have had new strains and a lot of diversity,” said Dr. Jay Calvert. “We thought we knew it was all about mutation changes in amino acids and the individual strains over time, but they take on new characteristics.”

With the onset of more common whole genome sequencing and recombination analysis, Dr. Calvert says there is another mechanism, and recombination seems to be a key factor.